Back

Revisiting prostaglandin biology in pulmonary arterial hypertension: targeting the EP4/ANXA2 axis

European Heart Journal

19 November 2025
Organised by: Logo
Read full article
ESC Journals BASIC SCIENCE

Contributors

Merve Keles
Merve Keles

Author

Allan Lawrie
Allan Lawrie

Author

Imperial College London London , United Kingdom of Great Britain & Northern Ireland

You may be interested in
thumbnail
Congress Presentation
Activation of prostaglandin E2 receptor 4 ameliorates pulmonary vascular remodeling and pulmonary hypertension via suppression of MEK/ERK activation
30 August 2025
thumbnail
Congress Presentation
The six-transmembrane protein Stamp2 protects from hypoxia-induced pulmonary vascular remodeling and pulmonary hypertension via actions in mononuclear cells and CXCL12
2 September 2019
thumbnail
Congress Presentation
Therapeutic role of Prostaglandin E2 receptor 4 stimulation in inflammatory cardiomyopathy
30 August 2021
thumbnail
Congress Presentation
Quality of life outcomes in patients with pulmonary hypertension receiving prostacyclin therapy: impact of anxiety, depression, sociodemographic and treatment-related factors
14 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources